Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marion Masitsa Malenge"'
Autor:
Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li, Roxanne Wouters, Tina Bjørnlund Bønsdorff, Asta Juzeniene, Srdan M. Dragovic
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-18 (2024)
Abstract Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administ
Externí odkaz:
https://doaj.org/article/6e80c74946a84d9b910f7c7c0d297563
Autor:
Ada H. V. Repetto-Llamazares, Jostein Dahle, Anne Hansen Ree, Marion Masitsa Malenge, Peter P. Ceuppens, Brian J. Middleton, Sebastian Patzke, Trond Stokke
Publikováno v:
Journal of Nuclear Medicine
Patients with non-Hodgkin lymphoma (NHL) who are treated with rituximab may develop resistant disease, often associated with changes in expression of CD20. The next-generation β-particle–emitting radioimmunoconjugate 177Lu-lilotomab-satetraxetan (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5658710a8822c0a7b502104b906a61f9
http://europepmc.org/articles/PMC7539655
http://europepmc.org/articles/PMC7539655
Autor:
Ada H. V. Repetto-Llamazares, Adam O'Shea, Bergthora Eiriksdottir, Roy H. Larsen, Trond Stokke, Marion Masitsa Malenge, Jostein Dahle
Publikováno v:
European Journal of Haematology. 101:522-531
Objectives To investigate the therapeutic potential of the next-generation anti-CD37 radioimmunoconjugate 177 Lu-lilotomab satetraxetan (177 Lu-lilotomab) in combination with the anti-CD20 antibody rituximab for treatment of mice with non-Hodgkin's l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2904577a122e2302906a3f0e730d880
https://doi.org/10.1111/ejh.13139
https://doi.org/10.1111/ejh.13139